February 2022 - Page 2 of 3 - PsychedelicNewsWire (PNW)

ThursdayFeb 17, 2022 10:15 am

Maryland Senators File Measure to Offer Veterans Free Access to Psychedelics

Earlier this week, a group of senators in the state of Maryland filed a measure which would establish a fund that could be used to support research into the therapeutic potential of psychedelics. The bill also called for providing free access to psychedelic drugs such as ketamine, MDMA and psilocybin for military veterans with PTSD. The bill, which was sponsored by Sen. Sarah Elfreth, would create a PTSD Alternative Therapies fund. The state fund would finance studies on psychedelics through Maryland’s Department of Health as well as offer cost-free access to alternative therapies. The measure stipulates that regulators will have…

WednesdayFeb 16, 2022 3:08 pm

Advocates Challenge DEA’s Proposal to Schedule Five Psychedelic Compounds

Researchers and advocates are challenging the DEA’s proposal to classify a series of psychedelic compounds under Schedule I of the Controlled Substances Act. The Drug Enforcement Administration published a scheduling proposal in the Federal Register in January that highlights its plan to ban the following tryptamines: DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPT. The DEA wants to classify these tryptamines under the same category as drugs such as LSD, cannabis and heroin. The agency stated that before it made the proposal, it conducted its own analyses as well as considered research and recommendations from the Department of Health and Human Services,…

TuesdayFeb 15, 2022 3:08 pm

Utah House Committee Approves Measure Allowing Research on Mental Health Benefits of Psychedelics

Last week, a House committee in the state of Utah passed a measure that would establish a task force to conduct research on and give recommendations for the therapeutic potential of psychedelic substances and regulations governing their legal use. The bill, which was sponsored by Rep. Brady Brammer, was approved by the House Health and Human Services Committee in a 10-to-1 vote. The bill stipulates that the task force would be required to research and give recommendations on drugs that could assist in mental illness treatment. The drugs to be considered included controlled substances that had the potential to manage,…

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

TuesdayFeb 15, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping Delic drive the conversation on psychedelics forward The company seeks to take this conversation further with its participation at this year’s Emerald Conference Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the…

MondayFeb 14, 2022 12:32 pm

What You Should Consider Before Investing in Psychedelics Space

The psychedelics industry is projected to grow at a compound annual growth rate of 14.5% in the short term, hitting $6.3 billion by 2026. Psychedelics present an attractive investment opportunity for any investors seeking to diversify their portfolio. However, like most major decisions in life, investing hard-earned money should be done with a lot of forethought and caution, especially when dealing with products that have a lot of room for growth, such as psychedelics. To help stake a profitable position in the burgeoning psychedelics space, potential investors will need to understand that experts’ expectations of psychedelics blowing up in the…

MondayFeb 14, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study…

FridayFeb 11, 2022 2:03 pm

Seattle Doctor Petitions DEA to Reschedule Psilocybin

Last week, Seattle doctor Sunil Aggarwal filed a petition with the Drug Enforcement Agency (“DEA”) challenging its Schedule I classification of psilocybin, which is the primary psychoactive component of hallucinogenic mushrooms. The federal petition filed by the doctor, who specializes in end-of-life care, requests that the DEA reschedule psilocybin as a Schedule II drug given the potential it has shown in relieving symptoms of various ailments including depression and anxiety caused by a terminal disease diagnosis. The petition also highlights how decades of research have shown that psilocybin has a low potential for abuse in comparison with other substances under…

FridayFeb 11, 2022 9:15 am

Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) Delic Labs to Present Latest Results and Insights from Its Extensive Experimental Studies on Cannabis Extraction at the Emerald Conference on February 28

Delic Lab’s President and Chief Science Officer, Dr. Markus Roggen, will present at the upcoming Emerald Conference on February 28 Delic Labs is a federally licensed research laboratory operating as part of the Delic Holdings ecosystem The laboratory focuses on extraction optimization, analytical testing, and chemical product and process development and is likely to continue supporting the cannabis industry with the latest technology and services as the cannabis market and cannabis extraction spaces mature Delic Holdings (CSE: DELC) (OTCQB: DELCF) recently announced that Dr. Markus Roggen – the President and Chief Science Officer of Delic Labs, a federally licensed cannabis…

ThursdayFeb 10, 2022 1:24 pm

Activists in Michigan File Psychedelic Legalization Voter Initiative

Activists in the state of Michigan have filed a ballot measure that will legalize the possession, cultivation and sharing of psychedelic substances as well as establish a system for the spiritual and therapeutic use of psychedelics, if approved. The Students for Sensible Drug Policy, a youth-led organization, and the Michigan Chapter of Decriminalize Nature worked together on this effort. The state’s ballot initiative would legalize various entheogenic substances, including DMT, peyote, mescaline, ibogaine, psilocin and psilocybin, for individuals aged 18 and above. During a recent interview, codirector of Decriminalize Nature Michigan Myc Williams stated that the two groups were excited…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: February 2022